Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AGPAT2 | O15120 | 4/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | ACSS2 | Q9NR19 | 3/20 | 0.40 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | HPGD | P15428 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.38 |
| ▸ | RPS6KA2 | Q15349 | 1/20 | 0.37 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PHGDH | O43175 | 1/20 | 0.37 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16595231 | 0.86 | LMNA (0.45) | AGPAT2NPC1RAB9AACSS2KDM4E | |
| SCHEMBL16595230 | 0.85 | KDM4E (0.42) | AGPAT2NPC1RAB9AACSS2KDM4E | |
| SCHEMBL17378554 | 0.79 | KDM4E (0.45) | AGPAT2NPC1RAB9AACSS2KDM4E | |
| SCHEMBL20799414 | 0.76 | RXFP1 (0.47) | KMT2ARXFP1PHGDH | |
| SCHEMBL14504050 | 0.74 | KDM4E (0.46) | AGPAT2NPC1RAB9AACSS2KDM4E | |
| SCHEMBL24045477 | 0.72 | ACSS2 (0.43) | AGPAT2NPC1RAB9AACSS2KDM4E | |
| SCHEMBL10238325 | 0.71 | KDM4E (0.52) | NPC1RAB9AACSS2KDM4EALDH1A1 | |
| SCHEMBL28287004 | 0.71 | AGPAT2 (0.49) | AGPAT2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL24662485 | 0.69 | KDM4E (0.55) | AGPAT2NPC1RAB9AKDM4EALDH1A1 | |
| SCHEMBL2362098 | 0.68 | KDM4E (0.55) | NPC1RAB9AACSS2KDM4EALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | BIOMARIN PHARMACEUTICAL INC. (US) | 2019-03-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10227323-B2 | Glucosylceramide synthase inhibitors for the treatment of diseases | GBA1, UGCG, GBA2 | AGPAT2 199/4885NPC1 74/4885RAB9A 1370/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.